{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:48:35Z","timestamp":1762004915559,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jac\/dkx195","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T03:14:15Z","timestamp":1495854855000},"page":"2570-2573","source":"Crossref","is-referenced-by-count":15,"title":["Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice"],"prefix":"10.1093","volume":"72","author":[{"given":"Alonso","family":"Heredia","sequence":"first","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Hassounah","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Montr\u00e9al, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Medina-Moreno","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Zapata","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhut M.","family":"Le","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingshan","family":"Han","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Montr\u00e9al, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"James S.","family":"Foulke","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Davis","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bryant","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Wainberg","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Montr\u00e9al, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"year":"2016","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"key\n\t\t\t\t20180313122626_dkx195-B1"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96\u2009week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B3","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B4","doi-asserted-by":"crossref","first-page":"22.","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mesplede","year":"2013","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/QAD.0000000000000199","article-title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","volume":"28","author":"Oliveira","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B8","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/QAI.0000000000000931","article-title":"Dolutegravir monotherapy in HIV-infected naive patients with <100,000\u2009copies\/mL HIV RNA load","volume":"72","author":"Lanzafame","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkv430","article-title":"Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients","volume":"71","author":"Gubavu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B11","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B12","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B13","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkw011","article-title":"Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients","volume":"71","author":"Rokx","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B14","doi-asserted-by":"crossref","first-page":"e0148231.","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients","volume":"11","author":"Baril","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B15","doi-asserted-by":"crossref","first-page":"e38853.","DOI":"10.1371\/journal.pone.0038853","article-title":"Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1","volume":"7","author":"Nischang","year":"2012","journal-title":"PLoS One"},{"author":"Blanco","key":"key\n\t\t\t\t20180313122626_dkx195-B16"},{"author":"Wijting","key":"key\n\t\t\t\t20180313122626_dkx195-B17"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","author":"Lataillade","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B19","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1128\/AAC.00651-09","article-title":"Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure","volume":"53","author":"Fransen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122626_dkx195-B20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/9\/2570\/24332466\/dkx195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T22:27:40Z","timestamp":1659047260000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/9\/2570\/3867672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,13]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx195","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,6,13]]}}}